Sulfonylurea therapy is associated with increased NT-proBNP levels in the treatment of type 2 diabetes

International Journal of Cardiology

Volumn 115, Issue 3, 2007, Pages 312-317

  Tildesley, Hugh D ^a,b   Aydin, Cristina M ^a   Ignaszewski, Andrew ^a,b   Strelzow, Jason A ^a   Yu, Eugenia ^a   Bondy, Greg ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cardiovascular disease; N terminal pro Brain Natriuretic Peptide; Sulfonylurea therapy; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CREATININE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; LIPID; METFORMIN; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; BODY MASS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DATA ANALYSIS; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; FEMALE; GENDER; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROBABILITY; REFERENCE VALUES; RISK ASSESSMENT; SEX FACTORS; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 33846593286     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.03.014     Document Type: Article

References (32)

1. American Diabetes Association. Consensus development conference on the diagnosis of coronary heart disease in people with diabetes. Diabetes Care 21 (1998) 1551-1559
2. Kannel W.B., Hjortland M., and Castelli W.P. Role of diabetes in congestive heart failure: The Framingham study. Am J Cardiol 34 (1974) 29-34
3. Nesto R.W., Bell D., Bonow R.O., et al. Thiazolidinedione use, fluid retention and congestive heart failure. Circulation 108 (2003) 2941-2948
4. Simpson S.H., Majumdar S.R., Tsuyuki R.T., Eurich D.T., and Johnson J.A. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 174 (2006) 169-174
5. Struthers A.D., and Morris A.D. Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet 359 (2002) 1430-1432
6. Seino Y., Ogawa A., Yamashita T., et al. Application of NT-proBNP and BNP measurements in Cardiac care: a more discerning marker for the detection and evaluation of heart failure. Eur J Heart Fail 6 (2004) 295-300
7. McCullough P.A., Omland T., and Maisel A.S. B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Rev Card Med 4 2 (2003) 72-80
8. Cheung B.M.Y., and Kumana C.R. Natriuretic peptides - relevance in cardiovascular disease. JAMA 280 (1998) 1983-1984
9. Takeyama H., Hino J., Minamino N., Kangawa K., Toshio O., and Matsuo H. Characterization of immunoreactive brain natriuretic peptide in human cardiac atrium. Biochem Biophys Res Commun 166 (1990) 1080-1087
10. Tabbibizar R., and Maisel A. The impact of B-type natriuretic peptide levels on the diagnoses and management of congestive heart failure. Curr Opin Cardiol 17 (2002) 340-345
11. Epshteyn V., Morrison K., Krishnaswamy P., et al. Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care 26 (2003) 2081-2087
12. Wilkins M.R., Redondo J., and Brown L.A. The natriuretic-peptide family. Lancet 349 (1997) 1307-1310
13. Yoshimua M., Yasue H., Okumura K., et al. Cardiac failure: different secretion patterns of atrial natriuetic peptide and brain natriuetic peptide in patients with congestive heart failure. Circulation 87 (1993) 464-469
14. Cowie M.R., and Mendez G.F. BNP and Congestive Heart Failure. Prog Cardiovasc Dis 44 (2002) 293-321
15. Ng L.L. Brain naturetic peptide (BNP) and diabetes mellitus. Diabet Med 21 (2004) 8-10
16. Nielsen L.S., Svanegaard J., Klitgaard N.A., and Egeblad H. N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. Eur J Heart Fail 6 (2004) 63-70
17. Raymond I., Groenning B.A., Hildbrandt P.R., et al. The influence of age, sex, and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 89 (2003) 745-751
18. Mueller T., Gegenhuber A., Poelz W., and Haltmayer M. Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart disease. Clin Chem Acta 341 (2004) 41-48
19. Roche Diagnostics. ProBrain Natriuretic Peptide; package insert (2004), Roche Diagnostics Inc, Indianapolis
20. Roche Diagnostics. ProBrain Natriuretic Peptide; package insert (2003), Roche Diagnostics Inc, Indianapolis
21. Bibbins-Domingo K., Ansari M., Schiller N.B., Massie B., and Whooley M.A. Is B-type natriuretic peptide a useful screening test for systolic or diastolic dysfunction in patients with coronary disease? Data from the heart and soul study. Am J Med 116 (2004) 509-516
22. Wu A.H.B., Omland T., Duc P., et al. The effect of diabetes on the B-type natriuretic peptide concentrations in patients with acute dyspnea: an analysis from the breathing not properly multinational study. Diabetes Care 27 (2004) 2398-2404
23. Magnusson M., Melander O., Israelsson B., Grubb A., Groop L., and Jovinge S. Elevated plasma levels of NT-proBNP in patients with type 2 diabetes without overt cardiovascular disease. Diabetes Care 27 (2004) 1929-1935
24. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Definition, classification and diagnosis of diabetes and other dysglycemic categories. CJD 27 Supp 1 (2003) 7-9
25. Swedberg K.B., Hall C., Nielsen O.W., et al. New frontiers in cardiovascular management clinical experiences and state-of-the-art research on N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP). A report from the First International Symposium on NT-proBNP. Cardiology Scientific Update (May 2003), Shell Medical Communication Inc, Toronto 1-6
26. Yeo K.T.J., Wu A.H.B., Apple F.S., et al. Multicenter evaluation of the Roche NTproBNP assay and comparison to the biosite triage BNP assay. Clin Chem Acta 338 (2003) 107-115
27. UK Prospective Diabetes Study Group. UKPDS 16: overview of 6 years of therapy of type 2 diabetes: a progressive disease. Diabetes 44 (1995) 1249-1258
28. Gulliford M., and Latinovic R. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study. Diabetes Metab Res Rev 20 (2004) 239-245
29. Miura T., and Miki T. ATP-sensitive K+ channel openers: old drugs with new clinical benefits for the heart. Curr Vasc Pharmacol 1 (2003) 251-258
30. Rana J.S., Mukamal K.J., Nesto R.W., Morgan J.P., Muller J.E., and Mittleman M.A. Effect of diabetes mellitus and its treatment on ventricular arrythmias complicating acute myocardial infarction. Diabet Med 22 (2005) 576-582
31. Eurich D.T., Majumdar S.R., McAlister S.R., Tsuyuki R.T., and Johnson J.A. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 28 (2005) 2345-2351
32. Nichols G.A., Koro C.E., Gullion C.M., Ephross S.A., and Brown J.B. The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev 21 (2005) 51-57